Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Rhea-AI Summary
Outlook Therapeutics (Nasdaq: OTLK) announced that CEO Bob Jahr participated in the Virtual Investor “Why Now” on-demand conference. The segment focuses on the company’s transition after FDA approval of LYTENAVA™ (bevacizumab-vikg) for wet age-related macular degeneration (wet AMD) in the U.S. on July 24, 2026.
According to Outlook Therapeutics, Jahr discussed moving from a development-stage to a commercial-stage company, U.S. launch preparations, the company’s existing commercial presence in Europe, and the opportunity for an FDA-approved ophthalmic bevacizumab in a market where bevacizumab is widely used off label. The webcast is now available for on-demand viewing.
Positive
- None.
Negative
- None.
Market Reaction – OTLK
Following this news, OTLK has gained 6.63%, reflecting a notable positive market reaction. Our momentum scanner has triggered 12 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.66.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | earnings and FDA approval | Negative | -14.9% | Quarterly loss and revenue decline accompanied the FDA approval and commercialization update. |
| Aug 12 | public offering | Negative | -19.3% | Common stock and warrant offering priced at $0.99 per share-and-warrant unit. |
| Aug 12 | proposed public offering | Negative | -19.3% | Company commenced an underwritten offering of common stock and accompanying warrants. |
| Aug 06 | earnings announcement | Neutral | -5.6% | Company scheduled third-quarter fiscal 2026 results and a corporate update webcast. |
| Jul 24 | FDA approval | Positive | +6.4% | FDA approved LYTENAVA as the first and only approved ophthalmic bevacizumab. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financing and earnings/FDA-related announcements were followed by negative reactions, while the FDA approval announcement was followed by a positive reaction.
Key Terms
wet AMD medical
off label regulatory
ophthalmic formulation medical
FDA-approved regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Video webcast now available here
ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that Bob Jahr, Chief Executive Officer, recently participated in the Virtual Investor “Why Now” on-demand conference.
During the segment, Mr. Jahr highlighted why he believes Outlook Therapeutics is entering a transformative period following the FDA’s approval of LYTENAVA™ on July 24, 2026, making it the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States. He discussed Outlook’s transition from a development-stage to a commercial-stage company and the significant opportunity to bring an FDA-approved ophthalmic bevacizumab to an established market where bevacizumab is already widely used off label. Mr. Jahr also highlighted LYTENAVA’s differentiated development and regulatory pathway, Outlook Therapeutics’ commercial launch preparations in the U.S., its existing commercial presence in Europe, and the potential for LYTENAVA™ to redefine the standard of care by providing physicians with an FDA-approved ophthalmic bevacizumab specifically developed for retinal use. With regulatory risk now substantially behind the Company and commercial execution taking center stage, Mr. Jahr outlined why he believes this represents a pivotal moment in Outlook Therapeutics’ evolution.
The video webcast is now accessible for on-demand viewing here.
JTC Team and Virtual Investor Co. are paid consultants to Outlook Therapeutics, Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Outlook Therapeutics, Inc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company's website and the SEC website for the latest information and filings on the Company.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Forward-Looking Statements
This press release contains statements that may or are considered “forward-looking statements”. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “may,” “on track,” “plan,” “potential,” “target,” “will,” or “would”, the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, express or implied discussions regarding the Company’s planned launch of LYTENAVA in the United States and other jurisdictions and the timing thereof; expectations concerning potential revenue generation from sales of LYTENAVA; expectations surrounding market adoption of LYTENAVA; potential additional marketing approvals; expectations regarding the potential impact of LYTENAVA in the retina community; new indications or labeling for LYTENAVA; Outlook Therapeutics development or future revenue plans for LYTENAVA generally; and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties, and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks in obtaining necessary regulatory approvals, the content and timing of decisions by regulatory bodies, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission (the SEC), including the Current Report on Form 8-K filed with the SEC on August 12, 2026, and future reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, tariffs, and trade tensions, fluctuations in interest rates and inflation, and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend, or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
